Christina Alsop, APRN
Acute Care · Reno, NVNPI 1013263003
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $549 of the $724 with a category attached, or 75.8%. 13 manufacturers reported payments, led by Astellas Pharma US Inc at 29.7% of the total. Reporting peaked in 2024 at $443 and has fallen 57.6% since, to $188 in 2025.
Across 22 payments — averaging $32.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$215
- AstraZeneca$171
- Sobi, Inc$79
- Daiichi Sankyo Inc.$77
- Incyte Corporation$28
- Gilead$27
- plus $128 from 7 others
What the payments were for
- Food & beverage$54976%
- Education$17524%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 4 | $215 |
| AstraZeneca | 4 | $171 |
| Sobi, Inc | 2 | $79 |
| Daiichi Sankyo Inc. | 3 | $77 |
| Incyte Corporation | 1 | $28 |
| Gilead | 1 | $27 |
| Tersera Therapeutics LLC | 1 | $25 |
| Pfizer | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $15 |
| Boston Scientific | 1 | $12 |
How this compares
$724 in reported general payments places this provider in the 65th percentile of 129 acute care providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 16 | $125 |
| Gabapentin | 11 | $87 |
| Prednisone | 13 | $40 |
Paid to pharmacies, not to this prescriber.
Other acute care in Reno
- Frank TalonReno$6K
- Sarah DeboorReno$5K
- Victoria LanskiReno$5K
- Michael ThompsonReno$4K
- Sarah FarberReno$4K
- Corinne CanaveroReno$4K
- Amelia ManguneReno$3K
- Brynja BowmanReno$3K
- Jeanine PackhamReno$2K
- Christopher HallReno$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.